Brian Powl Sells 6,414 Shares of Kura Oncology (NASDAQ:KURA) Stock

Kura Oncology, Inc. (NASDAQ:KURA) insider Brian Powl sold 6,414 shares of the company’s stock in a transaction dated Tuesday, January 27th. The shares were sold at an average price of $8.46, for a total transaction of $54,262.44. Following the completion of the transaction, the insider owned 183,275 shares in the company, valued at $1,550,506.50. This trade represents a 3.38% decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is available through this hyperlink.

Kura Oncology Price Performance

Shares of Kura Oncology stock opened at $8.22 on Friday. The company has a quick ratio of 5.12, a current ratio of 5.12 and a debt-to-equity ratio of 0.02. The stock has a market capitalization of $715.30 million, a price-to-earnings ratio of -3.31 and a beta of 0.25. Kura Oncology, Inc. has a twelve month low of $5.41 and a twelve month high of $12.49. The company has a 50-day simple moving average of $10.21 and a two-hundred day simple moving average of $9.04.

Kura Oncology (NASDAQ:KURA) last announced its earnings results on Tuesday, November 4th. The company reported ($0.85) EPS for the quarter, missing the consensus estimate of ($0.57) by ($0.28). Kura Oncology had a negative return on equity of 65.42% and a negative net margin of 208.48%.The business had revenue of $20.75 million for the quarter, compared to the consensus estimate of $17.48 million. Analysts forecast that Kura Oncology, Inc. will post -2.44 EPS for the current year.

Analysts Set New Price Targets

KURA has been the topic of several analyst reports. Leerink Partners set a $20.00 target price on Kura Oncology and gave the stock an “outperform” rating in a report on Tuesday, January 13th. UBS Group increased their price objective on shares of Kura Oncology from $14.00 to $16.00 and gave the stock a “buy” rating in a research note on Friday, November 14th. Barclays reissued an “overweight” rating and issued a $28.00 target price (up from $11.00) on shares of Kura Oncology in a report on Monday, November 24th. JMP Securities reaffirmed a “market outperform” rating and set a $24.00 price target on shares of Kura Oncology in a report on Monday, October 20th. Finally, Wedbush reiterated an “outperform” rating and set a $38.00 price target (up previously from $36.00) on shares of Kura Oncology in a research report on Friday, November 14th. Nine research analysts have rated the stock with a Buy rating, two have issued a Hold rating and two have issued a Sell rating to the stock. According to data from MarketBeat.com, Kura Oncology currently has an average rating of “Moderate Buy” and an average target price of $28.00.

Institutional Investors Weigh In On Kura Oncology

A number of hedge funds have recently made changes to their positions in KURA. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. grew its holdings in shares of Kura Oncology by 6.3% during the 1st quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 50,008 shares of the company’s stock valued at $333,000 after purchasing an additional 2,977 shares during the last quarter. Strs Ohio bought a new stake in shares of Kura Oncology during the first quarter worth $143,000. Wealth Enhancement Advisory Services LLC increased its holdings in shares of Kura Oncology by 169.3% during the second quarter. Wealth Enhancement Advisory Services LLC now owns 56,912 shares of the company’s stock worth $334,000 after buying an additional 35,779 shares in the last quarter. KLP Kapitalforvaltning AS lifted its stake in shares of Kura Oncology by 179.4% in the 2nd quarter. KLP Kapitalforvaltning AS now owns 19,000 shares of the company’s stock valued at $110,000 after acquiring an additional 12,200 shares during the last quarter. Finally, CWM LLC boosted its holdings in shares of Kura Oncology by 46.0% during the 2nd quarter. CWM LLC now owns 41,406 shares of the company’s stock valued at $239,000 after acquiring an additional 13,053 shares in the last quarter.

Kura Oncology Company Profile

Kura Oncology, Inc (NASDAQ: KURA) is a clinical-stage biopharmaceutical company focused on the discovery and development of targeted oncology therapies. Headquartered in La Jolla, California, the company leverages expertise in molecular biology and precision medicine to identify key drivers of cancer growth and design small-molecule inhibitors that block those pathways. Kura’s research platform integrates genomic insights with medicinal chemistry to advance candidates against well-validated targets in solid tumors and hematologic malignancies.

The company’s lead clinical candidate, tipifarnib, is a farnesyltransferase inhibitor being evaluated for the treatment of HRAS-mutant head and neck squamous cell carcinoma and various non-small cell lung cancers.